CBIO
Crescent Biopharma, Inc.
Price Chart
Latest Quote
$17.69
-0.52 (-2.86%)
Current Price
| Previous Close | $18.21 |
| Open | $18.39 |
| Day High | $18.39 |
| Day Low | $17.30 |
| Volume | 107,924 |
Stock Information
| Shares Outstanding | 27.57M |
| Total Debt | $1.54M |
| Cash Equivalents | $189.16M |
| Revenue | $11.88M |
| Net Income | $-162.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $487.80M |
| EPS (TTM) | $-5.88 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $412.84M |
| Sales | $11.88M |
| Income | $-162.08M |
| Book/sh | $5.41 |
| Cash/sh | $6.86 |
| Employees | 55 |
Financial Ratios
| Quick Ratio | 13.33 |
| Current Ratio | 13.78 |
| Debt/Eq | 0.84 |
Returns & Margins
| Gross Margin | 100.00% |
| Operating Margin | -2380.08% |
Ownership
| Insider Ownership | 6.16% |
| Institutional Ownership | 96.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.01 |
| P/S | 41.05 |
| P/B | 3.27 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $31.00 |
Technical Indicators
| SMA20 | $18.83 |
| SMA50 | $19.82 |
| SMA200 | $14.29 |
| RSI | 35.02 |
| ATR | 1.4386 |
| Shares Float | 14.60M |
| Short Float | 26.98% |
| Short Ratio | 10.21 |
| Rel Volume | 0.48 |
Performance History
| Week | -3.54% |
| Month | -4.27% |
| Quarter | +66.57% |
| 6 Months | +36.92% |
| YTD | +59.66% |
| Year | +33.31% |
| 3 Years | -90.06% |
| 5 Years | -105.85% |
| 10 Years | -102.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $17.69 | 119,500 |
| 2026-06-17 | $18.21 | 382,000 |
| 2026-06-16 | $17.95 | 124,200 |
| 2026-06-15 | $18.19 | 179,400 |
| 2026-06-12 | $17.92 | 182,000 |
| 2026-06-11 | $18.34 | 139,300 |
| 2026-06-10 | $17.57 | 169,100 |
| 2026-06-09 | $18.00 | 126,200 |
| 2026-06-08 | $17.28 | 238,300 |
| 2026-06-05 | $18.00 | 192,600 |
| 2026-06-04 | $18.45 | 157,800 |
| 2026-06-03 | $17.98 | 147,200 |
| 2026-06-02 | $17.01 | 437,100 |
| 2026-06-01 | $19.72 | 423,400 |
| 2026-05-29 | $20.65 | 419,800 |
| 2026-05-28 | $21.47 | 401,200 |
| 2026-05-27 | $20.79 | 447,000 |
| 2026-05-26 | $20.35 | 326,300 |
| 2026-05-22 | $20.74 | 140,400 |
| 2026-05-21 | $20.23 | 249,500 |
| 2026-05-20 | $18.91 | 107,800 |
| 2026-05-19 | $18.48 | 128,000 |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Crescent Biopharma: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-02-26T13:05:48ZHuge Insider Buying in MGM and Salesforce
24/7 Wall St. âĸ 2025-12-12T14:45:59Z
Crescent and Kelun-Biotech swap cancer asset rights in double deal
Pharmaceutical Technology âĸ 2025-12-05T14:36:39Z
Praxis soars higher; Bristol Myersâ CAR-T therapy wins broader use
BioPharma Dive âĸ 2025-12-05T10:00:00Z
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs
MT Newswires âĸ 2025-12-04T12:13:04ZCrescent Biopharma: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-06T12:40:53ZWith 36% stake, Crescent Biopharma, Inc. (NASDAQ:CBIO) seems to have captured institutional investors' interest
Simply Wall St. âĸ 2025-09-17T11:01:41Z
Crescent Biopharma: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-07-31T11:32:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $10,844,000 |
| Operating Revenue | $10,844,000 |
| Expenses | |
| Interest Expense | $2,185,000 |
| Total Expenses | $163,476,000 |
| Net Non Operating Interest Income Expense | $690,000 |
| Interest Expense Non Operating | $2,185,000 |
| Operating Expense | $163,476,000 |
| General And Administrative Expense | $25,390,000 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $-153,942,000 |
| Net Interest Income | $690,000 |
| Interest Income | $2,875,000 |
| Normalized Income | $-153,942,000 |
| Net Income From Continuing And Discontinued Operation | $-153,942,000 |
| Total Operating Income As Reported | $-152,632,000 |
| Net Income Common Stockholders | $-153,942,000 |
| Net Income | $-153,942,000 |
| Net Income Including Noncontrolling Interests | $-153,942,000 |
| Net Income Continuous Operations | $-153,942,000 |
| Pretax Income | $-151,942,000 |
| Interest Income Non Operating | $2,875,000 |
| Operating Income | $-152,632,000 |
| Per Share | |
| Diluted EPS | $-12.81 |
| Basic EPS | $-12.81 |
| Other | |
| Tax Effect Of Unusual Items | $0 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-149,673,000 |
| Reconciled Depreciation | $84,000 |
| EBITDA (Bullshit earnings) | $-149,673,000 |
| EBIT | $-149,757,000 |
| Diluted Average Shares | $10,413,649 |
| Basic Average Shares | $10,413,649 |
| Diluted NI Availto Com Stockholders | $-153,942,000 |
| Tax Provision | $2,000,000 |
| Research And Development | $138,086,000 |
| Selling General And Administration | $25,390,000 |
| Other Gand A | $10,833,000 |
| Salaries And Wages | $14,557,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $203,012,000 | $-15,479,000 |
| Total Assets | $240,293,000 | $35,617,000 |
| Total Non Current Assets | $3,638,000 | $813,000 |
| Other Non Current Assets | $1,323,000 | $813,000 |
| Current Assets | $236,655,000 | $34,804,000 |
| Other Current Assets | $1,278,000 | $38,000 |
| Prepaid Assets | $4,185,000 | $0 |
| Receivables | $18,000,000 | $0 |
| Accounts Receivable | $18,000,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $213,192,000 | $34,766,000 |
| Cash And Cash Equivalents | $213,192,000 | $34,766,000 |
| Cash Financial | $213,192,000 | $34,766,000 |
| Non Current Deferred Assets | - | $813,000 |
| Debt | ||
| Total Debt | $1,644,000 | $37,482,000 |
| Long Term Debt And Capital Lease Obligation | $1,209,000 | $37,482,000 |
| Current Debt And Capital Lease Obligation | $435,000 | - |
| Net Debt | - | $2,716,000 |
| Long Term Debt | - | $37,482,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $37,281,000 | $51,096,000 |
| Total Non Current Liabilities Net Minority Interest | $1,209,000 | $41,482,000 |
| Current Liabilities | $36,072,000 | $9,614,000 |
| Other Current Liabilities | $5,000,000 | $61,000 |
| Current Deferred Liabilities | $4,156,000 | $0 |
| Payables And Accrued Expenses | $21,360,000 | $9,538,000 |
| Interest Payable | $0 | $852,000 |
| Payables | $18,137,000 | $7,328,000 |
| Total Tax Payable | $8,000,000 | $0 |
| Accounts Payable | $9,997,000 | $107,000 |
| Equity | ||
| Common Stock Equity | $199,012,000 | $-15,479,000 |
| Preferred Stock Equity | $4,000,000 | - |
| Total Equity Gross Minority Interest | $203,012,000 | $-15,479,000 |
| Stockholders Equity | $203,012,000 | $-15,479,000 |
| Retained Earnings | $-171,809,000 | $-17,867,000 |
| Preferred Securities Outside Stock Equity | $0 | $4,000,000 |
| Other | ||
| Ordinary Shares Number | $30,446,767 | $19,500,000 |
| Share Issued | $30,446,767 | $19,500,000 |
| Tangible Book Value | $199,012,000 | $-15,479,000 |
| Invested Capital | $199,012,000 | $22,003,000 |
| Working Capital | $200,583,000 | $25,190,000 |
| Capital Lease Obligations | $1,644,000 | $0 |
| Total Capitalization | $203,012,000 | $22,003,000 |
| Additional Paid In Capital | $370,793,000 | $2,387,000 |
| Capital Stock | $4,028,000 | $1,000 |
| Common Stock | $28,000 | $1,000 |
| Preferred Stock | $4,000,000 | $0 |
| Long Term Capital Lease Obligation | $1,209,000 | $0 |
| Current Deferred Revenue | $4,156,000 | $0 |
| Current Capital Lease Obligation | $435,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,121,000 | $15,000 |
| Current Accrued Expenses | $3,223,000 | $2,210,000 |
| Dueto Related Parties Current | $140,000 | $7,221,000 |
| Net PPE | $2,315,000 | $0 |
| Gross PPE | $2,315,000 | $0 |
| Other Properties | $2,315,000 | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-144,451,000 |
| Operating Activities | |
| Operating Cash Flow | $-71,532,000 |
| Cash Flow From Continuing Operating Activities | $-71,532,000 |
| Investing Activities | |
| Capital Expenditure | $-72,919,000 |
| Investing Cash Flow | $-72,919,000 |
| Cash Flow From Continuing Investing Activities | $-72,919,000 |
| Financing Activities | |
| Repurchase Of Capital Stock | $-177,000 |
| Issuance Of Capital Stock | $321,887,000 |
| Financing Cash Flow | $322,984,000 |
| Cash Flow From Continuing Financing Activities | $322,984,000 |
| Net Other Financing Charges | $1,269,000 |
| Net Preferred Stock Issuance | $0 |
| Preferred Stock Issuance | $0 |
| Net Common Stock Issuance | $321,710,000 |
| Common Stock Issuance | $321,887,000 |
| Other | |
| Issuance Of Debt | $0 |
| End Cash Position | $213,299,000 |
| Beginning Cash Position | $34,766,000 |
| Changes In Cash | $178,533,000 |
| Proceeds From Stock Option Exercised | $5,000 |
| Common Stock Payments | $-177,000 |
| Net Issuance Payments Of Debt | $0 |
| Net Long Term Debt Issuance | $0 |
| Long Term Debt Issuance | $0 |
| Net Intangibles Purchase And Sale | $-72,000,000 |
| Purchase Of Intangibles | $-72,000,000 |
| Net PPE Purchase And Sale | $-919,000 |
| Purchase Of PPE | $-919,000 |
| Change In Working Capital | $-13,371,000 |
| Change In Other Working Capital | $4,318,000 |
| Change In Other Current Liabilities | $4,963,000 |
| Change In Payables And Accrued Expense | $363,000 |
| Change In Accrued Expense | $5,363,000 |
| Change In Payable | $-5,000,000 |
| Change In Account Payable | $2,081,000 |
| Change In Prepaid Assets | $-5,015,000 |
| Change In Receivables | $-18,000,000 |
| Changes In Account Receivables | $-18,000,000 |
| Other Non Cash Items | $82,397,000 |
| Stock Based Compensation | $13,300,000 |
| Depreciation Amortization Depletion | $84,000 |
| Depreciation And Amortization | $84,000 |
| Depreciation | $84,000 |
| Net Income From Continuing Operations | $-153,942,000 |
Fetched: 2026-06-19